MedPath

Study to Evaluate the Effect of the Smart Care-diabetes Management System on Subjects With Diabetes

Not Applicable
Completed
Conditions
Diabetes Mellitus
Interventions
Other: SMARTCARE service
Registration Number
NCT01505036
Lead Sponsor
SK Telecom Consortium
Brief Summary

SMARTCARE-diabetes management system' to evaluate the long-term effects on patients with diabetes.

Detailed Description

Primary Outcome Measure: To see if there's any change in HbA1C at Visit 6 (12M) compared Visit 2 (baseline) within each group and between the two groups.

All statistical analysis will progress through the SAS (Version 9.1). statistical test's significance level is 0.05. The principle is two-sided test.

Secondary Outcome Measures :

To see if there's any change in HbA1C at each Visit (Visit 3 - Visit 6) compared Visit 2 (baseline) within each group and between the two groups.

Add a Secondary Outcome Measure:

Treatment satisfaction (DTSQ, Diabetes Treatment Satisfaction Questionnaire): To see if there's any change in treatment satisfaction scores compared Visit 2 (baseline) within each group and between the two groups.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
554
Inclusion Criteria
  1. Type 2 diabetes
  2. At least 1 year after being diagnosed with Type 2 diabetes
  3. 7.0% ≤ HbA1c ≤ 10.0%
  4. Agreed to participate voluntarily in the study
Exclusion Criteria
  1. Severe chronic disease
  2. Diabetes mellitus complications
  3. Severe renal disease; Serum creatinin > 1.5(men), > 1.4 (women)
  4. Severe liver disease or AST, ALT ≥ 2.5 x ULN
  5. Known not to be taking medication reliably 3 months before the screening visit
  6. Insulin pump user
  7. Being registered for other clinical research or are planning to participate in other clinical researches during this study
  8. Pregnant woman
  9. Illiterate
  10. Being assessed irrelevant by the investigator

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
SMARTCARE serviceSMARTCARE serviceU-Health service
Primary Outcome Measures
NameTimeMethod
Rate of patients who attain,Hemoglobin A1C ≤ 7.0% and Blood pressure ≤ 130/80 and LDL-Cholesterol ≤ 100 or LDL-Cholesterol ≤ 70, all at 12 months.0 to 12 months

Rate of patients who attain, Hemoglobin A1C ≤ 7.0% and Blood pressure ≤ 130/80 and and LDL-Cholesterol ≤ 100 or LDL-Cholesterol ≤ 70, all at 12 months.

Secondary Outcome Measures
NameTimeMethod
Change in Hemoglobin A1C at visit 3,4,6 from baseline0 to 12 months

Change in Hemoglobin A1C at Visit3,4,6 from baseline. Reduce Hemoglobin A1c after study

change in QOL(Quality of life)0 to 12 months

Change in QOL(Quality of life) at Visit 6 from baseline.

Treatment satisfaction(DTSQ, Diabetes Treatment Satisfaction Questionnaire)0 to 12 months

change in Treatment satisfaction(DTSQ, Diabetes Treatment Satisfaction Questionnaire) at Visit 6 from baseline.

Changes in lipid profile at Visit 4 and 6 from baseline.0 to 12 months

Changes in lipid profile at visit 4 and 6 from baseline. Reduction of lipid profile

Changes in body weight0 to 12 months

Changes in body weight at each visit(visit 3,4,5,6) from baseline during 12 months. Reduction of body weight

Changes in Waist Circumference(WC)0 to 12 months

Changes in Waist Circumference(WC) at each visit(visit 3,4,5,6) from baseline during 12 months.

Reduction of Waist Circumference(WC)

Changes in Blood Pressure0 to 12 months

Changes in Blood Pressure at each visit(visit 3,4,5,6) from baseline during 12 months.

Changes in mean Blood Pressure

Trial Locations

Locations (1)

Medicrostar

🇰🇷

Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath